Xylazine Adulteration in Illicit Fentanyl: A Threat to Public Health

被引:3
作者
Marshall, Samuel A. [1 ]
Nelson, Leigh Anne [2 ]
机构
[1] Univ Missouri, Kansas City Sch Pharm, Kansas City, MO USA
[2] Univ Missouri, Kansas City Sch Pharm, Div Pharm Practice & Adm, 2464 Charlotte St, Kansas City, MO 64108 USA
关键词
xylazine; fentanyl; FAAX; toxicity; overdose; DRUGS;
D O I
10.1177/08971900241279635
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Xylazine-adulterated fentanyl (FAAX) is a critical public health concern in the United States (US), and the White House Office of National Drug Control Policy designated FAAX as an emerging drug threat in April 2023. Between 2020-2021, fatal xylazine-positive overdoses increased by 100-1127% depending on geographic region in the US. Objectives: This narrative review informs pharmacists about the clinical concerns, potential treatment strategies, and harm reduction approaches directed at FAAX. The objective is to provide pharmacists with the knowledge necessary to contribute to public health efforts in addressing this crisis. Results: Xylazine is commonly found as an adulterant in illicit drug combinations with fentanyl. Significant hypotension, and respiratory and CNS depression are associated with xylazine toxicity, and these effects may be synergistic with opioids. Standard naloxone doses are ineffective for xylazine toxicity, and there is no FDA-approved antidote for xylazine overdose in humans. Chronic use may lead to physiological dependence, withdrawal symptoms, and severe skin ulcerations. Pharmacists are crucial in addressing this crisis through patient education, advocating for testing and treatment, and promoting harm reduction measures. Conclusion: Xylazine and FAAX pose a substantial threat to public health. The synergistic effects of opioids increase the risk of fatal overdoses, highlighting the need for effective harm-reduction strategies. A comprehensive approach involving healthcare professionals, law enforcement, policymakers, and community organizations is required to address this public health issue, and pharmacists have an active role in mitigating the drug threat of FAAX.
引用
收藏
页码:264 / 269
页数:6
相关论文
共 50 条
  • [41] Comparative analysis of vapor profiles of fentalogs and illicit fentanyl
    Vaughan, Stephanie R.
    Fulton, Ashley C.
    DeGreeff, Lauryn E.
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2021, 413 (28) : 7055 - 7062
  • [42] Occupational Safety and Health and Illicit Opioids: State of the Research on Protecting Against the Threat of Occupational Exposure
    Basham, Casey
    Cerles, Audrey
    Rush, Margaret
    Alexander-Scott, Marissa
    Greenawald, Lee
    Chiu, Sophia
    Broadwater, Kendra
    Hirst, Deborah
    Snawder, John
    Roberts, Jennifer
    Weber, Angela
    Knuth, Martha
    Casagrande, Rocco
    NEW SOLUTIONS-A JOURNAL OF ENVIRONMENTAL AND OCCUPATIONAL HEALTH POLICY, 2021, 31 (03) : 315 - 329
  • [43] THE EFFECTS OF XYLAZINE AND FENTANYL ON VARIOUS HORMONES AND METABOLITES IN KARAKUL SHEEP AND A BLESBOK
    MARAIS, AL
    VANDERWALT, JG
    SKINNER, JD
    JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION-TYDSKRIF VAN DIE SUID-AFRIKAANSE VETERINERE VERENIGING, 1991, 62 (01): : 17 - 19
  • [44] Tranq Dope: Characterization of an ED cohort treated with a novel opioid withdrawal protocol in the era of fentanyl/xylazine
    London, Kory
    Li, Yutong
    Kahoud, Jennifer L.
    Do, Davis Cho
    Mulholland, Jamus
    Roque, Sebastian
    Stugart, Logan
    Gillingham, Jeffrey
    Borne, Elias
    Slovis, Benjamin
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2024, 85 : 130 - 139
  • [45] Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
    Burns, Glenn
    DeRienz, Rebecca T.
    Baker, Daniel D.
    Casavant, Marcel
    Spiller, Henry A.
    CLINICAL TOXICOLOGY, 2016, 54 (05) : 420 - 423
  • [46] Fentanyl-xylazine overdose deaths in the USA, 2018-2023
    Zhu, David T.
    Cano, Manuel
    INJURY PREVENTION, 2025,
  • [47] Clinical and demographic correlates of confirmed xylazine and levamisole exposure among ED patients with acute fentanyl overdose
    Aldy, Kim
    Culbreth, Rachel
    Love, Jennifer
    Wax, Paul
    Campleman, Sharan
    Brent, Jeffrey
    Krotulski, Alex
    Levine, Michael
    Buchanan, Jennie
    Manini, Alex
    CLINICAL TOXICOLOGY, 2023, 61 : 4 - 5
  • [48] The fentanyl epidemic in Estonia: factors in its evolution and opportunities for a comprehensive public health response, a scoping review
    Uuskula, Anneli
    Talu, Ave
    Vorobjov, Sigrid
    Salekesin, Maris
    Rannap, Jurgen
    Lemsalu, Liis
    Jarlais, Don Des
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 81
  • [49] "Tranq dope" opioid overdose: clinical outcomes for emergency department patients with illicit opioid overdose adulterated with xylazine
    Love, Jennifer
    Levine, Michael
    Aldy, Kim
    Brent, Jeffrey
    Krotulski, Alex
    Logan, Barry
    Vargas-Torres, Carmen
    Wax, Paul
    Manini, Alex
    CLINICAL TOXICOLOGY, 2022, 60 : 7 - 7
  • [50] "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl
    Silverstein, Sydney M.
    Daniulaityte, Raminta
    Martins, Silvia S.
    Miller, Shannon C.
    Carlson, Robert G.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 74 : 76 - 83